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Abstract: 
Small interfering RNA (siRNA) offers a great potential for the treatment of various diseases 
and disorders. Nevertheless, inefficient in vivo siRNA delivery hampers its translation into the 
clinic. While numerous successful in vitro siRNA delivery stories exist in reduced protein 
conditions, most studies so far overlook the influence of the biological fluids present in the in 
vivo environment. In this study, we compared transfection efficiency of liposomal formulations 
in Opti-MEM® (low protein content, routinely used for in vitro screening) and human undiluted 
ascites fluid obtained from a peritoneal carcinomatosis patient (high protein content, 
representing the in vivo situation). In Opti-MEM®, all formulations are biologically active. In 
ascites fluid, however, the biological activity of all lipoplexes is lost, except for lipofectamine 
RNAiMAX®. The drop in transfection efficiency was not correlated to the physicochemical 
properties of the nanoparticles such as premature siRNA release and aggregation of the 
nanoparticles in the human ascites fluid. Remarkably, however, all the formulations, except for 
lipofectamine RNAiMAX®, lost their ability to be taken up by cells following incubation in 
ascites fluid. To take into account the possible effects of a protein corona formed around the 
nanoparticles, we recommend to always use undiluted biological fluids for in vitro optimization 
of nano-sized siRNA formulations next to the conventional screening in low-protein content 
media. This should tighten the gap between in vitro and in vivo performance of nanoparticles, 
and ensure optimal selection of nanoparticles for further in vivo studies.  
 
 
 
 
Introduction: 
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Since the discovery of small interfering RNA (siRNA)1-2, a lot of effort has been put in 
translating it into the clinic for the treatment of different diseases3. In vitro there are numerous 
options to successfully deliver siRNA to cells under ‘reduced serum conditions’. In more 
complex ‘protein-rich’ biological fluids, however, the effect of the protein corona (being 
formed at the surface of the nanoparticles) on the aggregation, release, uptake, intracellular 
trafficking and transfection of nanoparticles should not be underestimated4-6. Unfortunately, 
upon screening tens of papers which aim to optimize siRNA carriers for future in vivo use, the  
nanoparticles are only evaluated in unrealistic protein-free conditions, in spite of the fact that 
human biological fluids like e.g. blood, serum, plasma, ascites fluids, sputa, synovial fluids, ... 
are easily accessible. As these undiluted biological fluids contain high concentration of proteins, 
they more closely resemble the in vivo situation. 
In vivo siRNA delivery is a complex process that includes both extracellular and 
intracellular barriers. Generally speaking, nanoparticles are expected to keep the cargo (i.e. 
siRNA) in an intact form while circulating in the biological fluids of the body. Also, pre-mature 
release of the siRNA from the nanoparticles and aggregation of siRNA nanoparticles in 
biological fluids are referred to as extracellular barriers for siRNA delivery7. While it is possible 
to determine the overall biological activity (i.e. gene knock down) of siRNA formulations in 
vivo, it is impossible to monitor siRNA release, aggregation and interaction of the formulations 
with biological membranes directly in vivo. Therefore, in vitro optimization of nanoparticle-
based siRNA delivery is still needed, though should be done under conditions which are as 
similar as possible to the in vivo situation in which the nanoparticles are intended to be used.  
A better understanding of our failure to efficiently deliver siRNA in vivo 8 should arise 
from a stronger knowledge on the physico-chemical and biophysical properties of siRNA 
delivery systems in the biofluids which are expected to be encountered. For patients diagnosed 
with peritoneal carcinomatosis, for example, the delivery of nanoparticles in the peritoneal 
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cavity is being considered as a promising future therapy. Locoregional anticancer therapy 
allows to target the peritoneal carcinomatosis while at the same time limiting systemic toxicity. 
After locoregional administration, nanoparticles come into contact with the peritoneal fluid 
present in the peritoneal cavity of these patients. Hence, understanding the influence of 
peritoneal fluid on the performance of the nanoparticles is crucial. In the current study, we 
investigated the ability of different PEGylated and non-PEGylated cationic liposomes to induce 
siRNA knockdown in a human ovarian cancer cell line. We resembled the expected in vivo 
situation by incubating the nanoparticles in undiluted ascites fluid isolated from a peritoneal 
carcinomatosis patient. Important parameters of the liposomal formulations that we studied 
were i) the release of siRNA in the ascites fluid, ii) the aggregation of the lipoplexes and iii) the 
effect of the biofluid on the cellular uptake of nanoparticles. All parameters were correlated 
with the biological performance of the liposomal formulations. Our results indicate that there 
is a large discrepancy between the high transfection potential of the nanoparticles seen under 
protein-free conditions, and their performance which remains after exposing them to a protein-
rich biofluid such as human ascites fluid.  
 
 
 
 
 
 
 
 
Experimental section  
Materials 
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(2,3-Dioleoyloxy-propyl)-trimethylammonium-chloride (DOTAP) and 1,2-Dioleoyl-sn-
glycero-3-phosphoethanolamine (DOPE), and N-palmitoyl-sphingosine-1-
{succinyl[methoxy(polyethylene glycol)2000]} (C16 mPEG 2000 Ceramide) were purchased 
from Avanti Polar Lipids  (Alabaster, AL, USA). Chloroform, 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES), 3-(4,5-Dimethyl-2-thiazolyl)-2,5-diphenyl-2H-
tetrazolium bromide (MTT) and sodium chloride (NaCl) were purchased from Sigma Aldrich 
(Bornem, Belgium).  
Penicillin-Streptomycin (5000 U/ml), Lipofectamine® RNAiMAX Transfection Reagent (LF), 
L-Glutamine (200 mM), 0.25% Trypsin-EDTA (1X) Phenol Red, McCoy's 5A (Modified), 
Opti-MEM® and 1,1'-dioctadecyl-3,3,3',3'-tetramethylindodicarbocyanine perchlorate (DID) 
(λex= 644 nm, λem= 665 nm) were purchased from Invitrogen (Merelbeke, Belgium). 
Luciferase Assay Substrate was purchased from Promega (Madison, WI, USA). Fetal Bovine 
Serum (FBS) was purchased from HyClone® Thermo Scientific (Cramlington, UK). Passive 
Lysis Buffer and Luciferase Assay Kit were purchased from (Promega, Leiden, Netherlands). 
Negative control siRNA (siNEG) and Luciferase siRNA (siLuc) were purchased from 
(Eurogentec, Searing, Belgium).   
Preparation and characterization of the lipoplexes (LPXs) 
 
Liposomes corresponding to 5 mM of DOTAP and 5 mM of DOPE lipids were prepared by 
mixing the appropriate amount of lipids in a round bottomed flask before evaporation.  
PEGylated liposomes were prepared by adding the desired amounts of C16 Cer-PEG dissolved 
in chloroform (corresponding to 5 mol%) to the lipids before evaporation. A lipid film was 
formed by rotary evaporation of the chloroform at 40°C. Liposomes were prepared by 
rehydrating the lipid film with HEPES buffer (20 mM, pH 7.4), followed by sonication using 
a probe sonicator (Branson Ultrasonics Digital Sonifier®,Danbury,USA). LPXs of +/- charge 
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ratio of 8 were prepared by adding appropriate amounts of liposomes to siRNA. The mixture 
was incubated at room temperature to allow formation of the LPXs. Lipofectamine 
RNAiMAX® LPXs were prepared as described by the manufacturer. Briefly, appropriate 
volume of  Lipofectamine RNAiMAX® was added to a solution of respectively siNEG,  ssiLuc 
or fluorescently labeled siRNA and incubated at room temperature for 15 minutes before use. 
Throughout the manuscript Lipofectamine RNAiMAX® lipoplexes will be termed LF-LPXs. 
The average size and zeta potential of all formulations were measured  by a Zetasizer Nano-
ZS (Malvern, Worcestershire, UK). 
 Cell culture 
The human ovarian cancer cell line SKOV-3 which stably expresses firefly luciferase was used 
for in vitro experiments. Cells were cultured in McCoy's 5A medium supplemented with FBS, 
Penicillin-Streptomycin. Cells were cultured until 80% to 90% confluency and detached from 
tissue culture dishes with 0.25% trypsin. Cells were maintained in an incubator at 37°C in a 
humidified atmosphere with 5% CO2.   
Transfection efficiency  
SKOV-3 cells were cultured overnight on 24-well plates (35,000 cells/well) in 500 µl of 
medium containing 10% FBS . Then, cells were washed and incubated with the LPXs and LF-
LPXs in Opti-MEM® during 4 h. After 4 h of incubation, the transfection medium was replaced 
by culture medium and cells were returned to the incubator for 24 h. The siLuc concentration 
in the wells equaled 25 nM. LF-LPXs, prepared as recommended by the manufacturer, were 
used as positive control. Each LPX containing siLuc was compared with its own control (e.g. 
siNEG).  
After overnight incubation, cells were lysed with Passive Lysis Buffer and analyzed for firefly 
luciferase expression using the luciferase assay kit (Promega). The bioluminescence (Relative 
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Light Units, RLU) was measured using a GloMax Luminometer (Promega). The percentage of 
luciferase down regulation was determined by the following equation:  
% transfection = 100 – (100 x RLULuc/RLUNEG), where RLUNEG and RLULuc are the mean 
bioluminescence as measured for respectively siNEG and siLuc. The data shown in Figure 2 is 
based on 3 experiments performed on 3 different days.  
For transfections in the ascites fluid, 300 µl LPXs (of each formulation) were first added to 700 
µl  ascites fluid and incubated for 1 h. Then, 300 µl of this mixture was added to 700 µl of Opti-
MEM® in each well of a 24 well-plate. Thereafter, the medium was replaced with growth 
medium and cells were returned to the incubator for 24 h as described above.  
So named ‘upside-down transfections’ were performed as follows: 300 µl LF-LPXs were 
incubated for 1 and 3 h at 37°C in 700 µl of human ascites fluid . SKOV-3 cells were cultured 
(during 24h) on 12 mm coverslips. Subsequently the cells (on the coverslips) were mounted 
upside-down on plastic tubes (diameter 1.3 cm, height 0.9 cm), filled with 700 µl Opti-MEM®. 
Then, 300 µl LF-LPXs were added to these tubes as such or after incubation in the ascites fluid. 
After 4 h of exposing the LF-LPXs to the cells, the coverslips were placed in the wells of a 24-
well plate and kept in the incubator for 24 h after adding growth medium to the cells. 
Subsequently the cells were lysed and the percentage of luciferase inhibition was calculated as 
mentioned above. It should be noted that in this upside-down transfection mode, precipitation 
of LF-LPXs on the cells due to gravity is avoided. 
Statistical analysis (shown in Figure 1.) was performed using GraphPad Prism 6 (GraphPad®, 
USA). Statistically significant differences were calculated by using an analysis of variance 
(ANOVA) at a 0.05 significance level, followed by Sidak’s post test. For each formulation, 
transfection experiment carried-out in Opti-MEM® were compared to those in ascites. 
Fluorescence Correlation Spectroscopy on LPXs  
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Fluorescence Correlation Spectroscopy (FCS) is a microscopy-based technique that monitors 
the fluorescence intensity fluctuations of (fluorescent) molecules diffusing in and out of the 
focal volume of a confocal microscope7, 10. Single color FCS measurements were performed on 
LPXs containing 30% Cy5 siRNA, with a +/- charge ratio of 8. Five µl of such LPXs was  
diluted to a final volume of 45 µl  HEPES buffer or 45 µl ascites fluid (~ 90 vol% of  biofluid); 
The samples were analysed by FCS  immediately, 1 h and 24 h after incubation in the biofluids 
at 37°C. During the incubation and FCS measurements, the well plate was covered with 
Adhesive Plates Seals (Thermo Scientific, UK) to avoid evaporation of the sample and to 
minimize flow. FCS measurements were performed on the experimental set-up described 
before7.   
Fluorescence single particle tracking (fSPT) 
Fluorescence single particle tracking (fSPT) is a fluorescence microscopy technique which is 
very well suited to determine diffusion/aggregation of nanoparticles in undiluted biological 
fluids, as was previously shown 11.  
fSPT measurements were performed on LPXs (Cationic, 5% C16 Cer-PEG and LF-LPXs), 
labeled with DID or containing Alexa-Fluor 488 (AF-488) labeled siRNA. LPXs were 
dispersed in biofluids as follows. First, formulations were diluted 400 times in HEPES buffer. 
Then 5 µl was added to 45 µl of human ascites fluid  (~ 90 vol% of  biofluid), and incubated 
for respectively 1, 2 and 3 h at 37°C in a 96-well plate (Greiner bio-one, Frickenhausen, 
Germany). At the end of the incubation time, the samples were placed on a custom-built fSPT 
set-up11 and movies were recorded at about 5 μm above the bottom of the 96-well plate. Videos 
were analyzed as was previously explained using the following values of viscosity at room 
temperature: 1.39 cP for the ascites fluid and 0.94 cP for HEPES buffer7. Human ascites fluid 
was obtained from a patient diagnosed with peritoneal carcinomatosis at the medical oncology 
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department of Ghent University hospital (approved by the ethics committee of the Ghent 
University hospital  (# 2013/589)). 
 
Internalization of siRNA into SKOV-3 cells 
SKOV-3 cells were plated on 24-well plates (35,000 cells in each well) and allowed to grow in 
an incubator for 24 h. For uptake experiments, cells were incubated in Opti-MEM® with 
fluorescent LPXs containing 10% of AF-488 siRNA for 4 h at 37°C and 4°C. At the end of the 
incubation, cells were washed extensively with warm growth medium and PBS, then detached 
using trypsin and analyzed by FACS (FACSCalibur Flow Cytometer, BD Biosciences, USA). 
Uptake experiments were performed with LPXs as such (directly after preparation), or after 
incubation of the LPXs with ~70% ascites fluid for 1 h before adding them to the cells, as 
described above under transfection efficiency.  
 
 
 
 
 
 
 
 
 
 
Results  
Characterization of the liposomes and LPXs in HEPES buffer  
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As depicted in table 1, all the formulations resulted in nano-sized vesicles, as determined by 
dynamic light scattering (DLS). Despite of the fact that the average size of the LF based 
liposomes (LF-LP) and LF lipoplexes (LF-LPXs) were in the same range as the other 
formulations, the polydispersity of the LF-LP and LF-LPXs was higher  (polydispersity index 
(PDI) > 0.5). The size increased for all formulations upon complexation of the liposomes with 
siRNA (except for LF-LPXs). 
The cationic liposomes and LPXs  showed the highest positive surface charge (as reflected from 
their zeta-potential). As expected, PEGylation lowered the surface charge of the liposomes and 
the  LPXs. LF-LP and LF-LPXs showed an intermediate surface charge.   
 
Transfection efficiency of the LPXs in protein-free and protein-rich conditions  
To evaluate the ability of the LPXs to knockdown the expression of a specific gene, 
SKOV-3 cells stably expressing luciferase were incubated with the LPXs containing siRNA 
against luciferase (siLuc). To verify the knockdown specificity, formulations loaded with a 
scrambled sequence (siNEG) were used as well.  
Figure 1 (dark grey bars) demonstrates the transfection efficiency of the LPXs following 
incubation in Opti-MEM®. All the formulations efficiently down regulated luciferase 
expression. 
Considering the fact that nanoparticles for in vivo intraperitoneal gene therapy will come into 
contact with peritoneal fluids, we were interested to see whether incubation of the LPXs in the 
ascites fluid obtained from a human peritoneal carcinomatosis patient would influence their 
transfection efficiency. The white bars in Figure 1 show a dramatic significant decrease in the 
transfection efficiency for the cationic LPXs and 5% C16 Cer-LPXs, while the LF-LPXs remain 
active. This raised the question as to why the LPXs and 5% C16 Cer-LPXs significantly lost 
their biological activity upon exposure to human ascites fluid.  
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Release of siRNA from LPXs in undiluted human ascites fluid  
A possible reason why LPXs are less efficient in human ascites fluid could be a premature 
release of siRNA from the formulations. Indeed, the more siRNA is released from the carriers, 
the less siRNA remains available for uptake in cells. As demonstrated previously by us, FCS is 
a suitable method to determine the amount of siRNA that is present in nanocarriers9-10. 
Likewise, FCS can be used to follow the release of siRNA from nanoparticles upon incubating 
them in buffer and biological fluids7.  
Figure 2 shows the percentage of siRNA that is associated with the different formulations in 
HEPES buffer immediately following preparation (e.g. complexation efficiency) and after 
incubation for 1 h and 24 h in human ascites fluid (90% vol). In HEPES buffer (grey bars), 
cationic LPXs show the highest complexation efficiency, with more than 90% of the siRNA 
associated to the cationic liposomes. PEGylation of the cationic liposomes seems to reduce the 
complexation efficiency as only 75% of the siRNA is bound to the 5% C16-Cer LPXs. LF- 
LPXs have the lowest loading efficiency with 65% of  siRNA complexed .  
Following 1 h of incubation in human ascites fluid (white bars), all formulations release a 
substantial amount of  the initially complexed siRNA, leaving only 50%, 40% and 40% of 
siRNA complexed in cationic LPX, 5% C16-Cer LPXs and LF-LPXs ,respectively. Following 
24 h of incubation in human ascites fluid, release of siRNA continues, resulting in less than 
20% of siRNA remaining complexed in all the formulations (dark grey bars). Taken together, 
human ascites fluid induces a massive release of siRNA from all liposomal formulations, 
reducing the amount of complexed siRNA that remains available for biological activity to about 
20%.  
The substantial loss of siRNA following incubation in ascites fluid could explain the lower 
transfection efficiency of the cationic LPXs and 5% C16 Cer-LPXs in Figure 1. Nevertheless, 
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also LF-LPXs retain only 20% of complexed siRNA, while maintaining their biological 
activity. In a next step, we evaluated the aggregation of the complexes in the undiluted human 
ascites fluids and whether or not this aggregation influences the biological activity of the 
complexes.  
 
Aggregation of the LPXs in undiluted human ascites fluid 
In our previous study7, we have shown that dynamic light scattering (DLS) is not an ideal 
technique for quantifying the extent of aggregation of nanocarriers in (undiluted) ascites fluids, 
simply due to light scattering that results from the high amount of proteins in such samples. In 
our hands fSPT has proven to be superior over DLS to study aggregation of nanoparticles in 
biological fluids7, 11-13. Figure 3a shows the size distributions of the cationic LPXs incubated in 
undiluted human ascites fluid (~ 90 vol% of biofluid) during 1, 2 and 3 h. In HEPES buffer the 
average diameter of the cationic LPXs is about 200 nm. In ascites fluid aggregation in time 
clearly occurs with the formation of 1-2 µm sized aggregates. 5% C16 Cer-LPXs have an 
average size of 150 nm in HEPES buffer (Figure 3b, black curve). Following 1 h of incubation 
in ascites fluid, the size distribution is (very) slightly shifted towards the right showing 
aggregation of a specific population of particles, particularly those that were initially smaller 
than 100 nm (Figure 3b, red curve). After 2 h of incubation, aggregation seems to become more 
outspoken, with an average diameter of 200 nm (Figure 4b, blue curve). No further aggregation 
was observed following 3 h of incubation (Figure 4b, green curve). Figure 3b confirms our 
previous results that PEGylation protects liposomes from aggregation in undiluted human 
ascites fluid7.  
LF-LPXs showed a high polydispersity in HEPES buffer, with particles ranging from tens of 
nanometers up to 1 µm in size  (Figure 3c, black curve). Following incubation in ascites fluid 
we observed a slight aggregation after 1 h of incubation (Figure 4c, red curve), followed by a 
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pronounced aggregation after 2 and 3 h (Figure 3c, green and blue curve), with the presence of 
micron-sized particles.  
 
Based on the data in Figure 4c, it is clear that very severe aggregation occurs in ascites fluids 
for LF-LPXs. Figure 1 demonstrates that LF-LPXs exposed to ascites fluids show the highest 
transfection efficiency, while the (more) colloidally stable cationic LPXs and 5% C16 Cer-
LPXs lose their biological activity in ascites fluid (Figure 1, white bars). One possible reason 
for these observations could be that the larger LF-LPXs aggregates rapidly sediment onto the 
cells during transfection, leading to a forced increased uptake and transfection efficiency. To 
test this hypothesis, the cell uptake of the lipoplexes was evaluated before and after incubation 
of the formulations in ascites fluid.  
 
Influence of ascites fluid on the cellular uptake of the LPXs by SKOV-3 cells  
To test the extent of LPX uptake in cells after incubation with ascites fluid, we exposed SKOV-
3 cells to LPXs loaded with fluorescently labeled AF-488 siRNA and quantified their uptake 
by flow cytometry. Figure 4a indicates that in Opti-MEM® (and at 37°C) the various types of 
LPXs carried the fluorescent siRNA into SKOV-3 cells. At 4°C, intracellular AF-488 
fluorescence was minimal (data not shown), indicating that at 37°C the LPXs were indeed 
internalized and did not just attach at the surface of the cells. When the same experiment was 
performed with LPXs that were incubated in ascites fluid for 1 h, the cationic LPXs and the 5% 
C16 Cer-LPXs completely lost their ability to carry the fluorescent siRNA into the cells, as 
depicted in Figure 4b. Only LF-LPXs were still efficiently internalized into SKOV-3 cells.   
         
Aggregation is not the sole determinant of in vitro transfection efficiency 
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  As Figure 3c demonstrates that mainly LF-LPXs form large aggregates in ascites fluid, which 
may easily sediment on the cells, we wondered whether those severe aggregates explain why 
LF-LPXs keep transfecting the cells. Therefore, we tested the ability of LF-LPXs to transfect 
SKOV-3 cells in an “upside-down transfection mode” where cells are positioned at the top 
surface of the LPXs dispersions, thus avoiding the spontaneous sedimentation of aggregates on 
the cells. Upside-down transfections were performed with LF-LPXs in Opti-MEM® and with 
LF-LPXs that were incubated in ascites fluid during 1 or 3 h. As depicted in Figure 5, in Opti-
MEM® luciferase down regulation remained 80%, which is similar as in the ‘normal 
transfection mode’ (see Figure 1). This demonstrates that in Opti-MEM®, LF-LPXs can equally 
well transfect cells which are below (Figure 1) or on top (Figure 5) of the LF-LPX solution, 
thereby ruling out the possibility that only aggregates contribute to the transfection efficiency. 
Following incubation of LF-LPXs for 1 h and 3 h in the ascites fluid, the transfection efficiency 
decreased to 40% in the upside-down transfection mode (Figure 5), while this decrease was not 
observed in the ‘normal transfection mode’ (see Figure 1). Our data suggest that in the ‘upside-
down transfection mode’, the non-aggregated fraction of the LF-LPXs can reach 40% of the 
cells, while in the ‘normal transfection mode’ an additional 40% of cells are transfected by LF-
LPXs aggregates that are formed in ascites fluid and sediment onto the cells. Therefore, 
aggregates can indeed contribute to the transfection efficiency, though they are not solely 
responsible for the observed biological activity.  
 
 
 
 
Discussion  
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siRNA mediated downregulation of disease related proteins is a very promising 
therapeutic application. Although numerous efficient nanoparticles have been identified for 
successful siRNA delivery in vitro, the actual number of formulations that withstand the harsh 
in vivo conditions is extremely disappointing. In vivo, nanoparticles face additional barriers 
such as protein-rich biofluids which are not present in the widely used protein-free conditions 
when screening nanoparticles in vitro. Hence, the influence of extracellular fluids on the 
nanoparticles performance after administration to the human body is often overlooked. In this 
study, we evaluated the potential of non-PEGylated and PEGylated liposomal formulations to 
successfully deliver siRNA to a human ovarian cancer cell line. Considering the potential use 
of locoregional administration of lipid-based siRNA carriers to treat peritoneal metastasis, 
nanoparticles in this study were tested in human ascites fluid, obtained from a carcinomatosis 
patient. Additionally, biological activity was determined in the widespread used low-protein 
content medium Opti-MEM®. Importantly, solely based on transfections in this low-protein 
medium, all formulations performed up to expectations. Unfortunately, when incubating the 
formulations in a high-protein content medium (i.e. ascites fluid in this study), only LF-LPXs 
were able to keep their original efficiency. To explain the drop in transfection efficiency, we 
evaluated three important properties of the nanoparticles, namely premature siRNA release, 
nanoparticle aggregation and cellular uptake in the presence of human ascites fluid.  
Complexation of siRNA to (cationic) carriers is necessary to enhance the cellular uptake of 
these negatively charged nucleic acids. Hence, premature release of siRNA from the 
nanocarriers in the biofluids, before cellular uptake has taken place, will result in a lower 
amount of siRNA that is able to reach the cytoplasm of the cells. Using Fluorescence 
Correlation Spectroscopy, we found that all tested formulations showed release of siRNA in 
the presence of ascites fluid. This siRNA release most likely results from competition between 
siRNA and the abundantly present negatively charged proteins in the human ascites fluid for 
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binding to the positively charged liposomes. Although testing release of siRNA in protein-rich 
conditions can tell us something about the fraction of siRNA that is lost, it is important to note 
that the absolute values of complexed siRNA were not predictive for the expected biological 
activity. Indeed, all formulations end up with almost the same amount of remaining siRNA 
following 24 h of incubation (Figure 2), while clear differences in transfection efficiency exist 
(Figure 1). 
As the uptake of nanoparticles is both charge and size dependent, aggregation of nanoparticles 
can potentially influence the uptake profile and subsequent transfection efficiency 14. Therefore, 
we evaluated if aggregation of the nanoparticles was related to the obtained biological activity. 
On the contrary to the release profile, the differences in aggregation between the formulations 
is much more pronounced. Aggregation is most pronounced in the case of the cationic LPXs, 
while in the case of C16 Cer-LPXs the PEG chains protect the LPXs from aggregation. One 
could argue that the formation of large aggregates could be the reason why lipofectamine 
RNAiMAX® is still efficiently transfecting cells after incubation in ascites fluid. Indeed, 
aggregates are expected to sediment onto cells and in this way, a larger amount of nanoparticles 
(and thus concentration of siRNA) comes into contact with cells during the 4 hours incubation 
period. When ruling out this sedimentation with an upside-down transfection setup, however, 
LF-LPXs still retained 50% of their transfection efficiency, demonstrating that aggregation 
alone cannot be the sole reason for the better transfection efficiency of LF-LPXs. Aggregation 
of particles remains however extremely important for the in vivo situation, as large aggregates 
can cause severe toxicity such as blocking the blood capillaries. Therefore, aggregation studies 
remain predictive of the suitability of nanoparticles for the in vivo situation and one should keep 
in mind that strongly aggregated nanoparticles have no future for in vivo use, even when high 
in vitro transfection efficiencies were obtained.  
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Cellular uptake is a first important step of the intracellular journey of nanoparticles. 
Importantly, the drop in the transfection of the cationic and PEGylated LPXs does correspond 
with the observation that the complexes are no longer internalized into cells after incubation in 
ascites fluid (Figure 4b). As we measure the uptake based on fluorescent siRNA, a pre-mature 
release of siRNA in the ascites fluid would lower the amount of complexed siRNA that can 
enter the cells and be detected. The amount of released siRNA in ascites fluid is however 
comparable for the three formulations studied (Figure 2). As all formulations contained at least 
still 40% of complexed siRNA, the possible internalization of the complexes should be 
detectable. The fact that only LF-LPXs are still taken up in the cells after pre-incubation in 
ascites fluid could in theory also be ascribed to the sedimentation of a larger amount of particles 
onto the cells. As described above, however, LF-LPXs also transfect (and thus are taken up) in 
an upside down transfection setup to which larger aggregates do not contribute.  
When nanoparticles are dispersed in extracellular fluids, proteins in these biofluids may bind at 
the surface of the nanoparticles, forming a so-called protein corona. It has been shown that the 
protein corona formed around transferrin-functionalized nanoparticles impairs their ability to 
bind transferrin receptors on the cell surface following incubation in fetal bovine serum and 
human serum15-16. Also, the protein corona can alter the intracellular processing of particles, 
increasing the fraction that accumulates in the lysosomes17. Both the protein composition of the 
biofluid and the surface properties of the nanoparticles will determine the composition of the 
protein corona that is eventually formed. We have previously shown that the protein 
concentration in human ascites fluid is half the concentration of proteins present in human 
serum, while the protein composition of human ascites fluid is very similar to human serum, 
with albumin as main fraction (62%) 7. We hypothesize that the poor uptake observed following 
incubation of cationic LPXs and PEGylated LPXs in the ascites fluid results from the surface 
coating of these formulations with negatively charged proteins 18. It is worth mentioning that 
18 
 
this is not the first study showing that nanoparticles lose their ability to interact with biological 
membranes following incubation with a protein-rich biological environment. Interestingly, very 
recently also Hadjidemetriou et al. reported that bare and PEGylated liposomes significantly 
lost their ability to internalize into cells following incubation in undiluted plasma19. This points 
out that the detrimental effect of human ascites fluid on the internalization of nanoparticles 
could be a common problem for many nanoparticle formulations exposed to various biological 
fluids. As for nucleic acid delivery, uptake is necessary for biological activity, testing the uptake 
of gene delivery systems following incubation in undiluted biological fluids is extremely 
important and should become a routine test before performing in vivo studies. Taken together, 
the “protein corona field” is rapidly growing with new findings that are extremely important 
for translating the in vitro to the in vivo situation, but is still not getting enough attention among 
scientists in the RNAi delivery community.  
 
Conclusions 
Importantly, we found that good complexation and transfection properties in reduced serum 
conditions like Opti-MEM® are not predictive to the actual performance of nanoparticles after 
being exposed to more complex biological fluids such as human ascites fluid. Based on our 
results the most important factor that eventually determines the biological activity is the 
biological fluid in which the particles are incubated with prior to adding them on cells. The 
composition of the biological fluid may substantially influence the extent of release, 
aggregation, uptake and biological activity of nano-sized siRNA formulations. Therefore, we 
strongly recommend to perform in vitro optimization of nano-sized siRNA formulations in 
undiluted biological fluids taking into account the route of administration, regardless of the type 
of the formulation (lipid–based or polymer-based), before assessing the transfection efficiency 
of nanoparticles in vivo. As most biofluids such as peritoneal fluid in the case of intraperitoneal 
19 
 
gene delivery and serum or blood in the case of intravenous (IV) delivery are relatively easily 
accessible, testing nanoparticles in these more complex biological environments is very feasible 
and far more representative for the in vivo situation. Based on assays performed in protein free 
(Opti-MEM®) conditions only, one runs the risk to select nanoparticles that are able to cross an 
empty street, hoping they will also survive the busy traffic conditions in vivo. Just like earning 
a driving license, however, nanoparticles should be tested in realistic in vitro conditions so that 
in vivo animal testing can be restricted to only those particles that passed the relevant screening 
conditions.    
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Tables 
Table 1. 
Z-Average diameter and zeta potential of the different formulations used in this study 
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Legends 
Figure 1 
Formulation  Z‐Average 
diameter ± 
SD 
(nm) 
Polydispers
ity index 
(PDI)  
Zeta‐
potential  
(mV) 
(mean ± 
SD) 
Abbreviat
ion 
Cationic  Liposomes  85 ± 1 0.2 56 ± 1 
Cationic 
LP 
LPX 107 ± 1 0.2 53 ± 1 Cationic LPXs 
5% C16 Cer‐
PEG 
Liposomes  115 ± 2 0.2 6 ± 1  5% C16 Cer‐LP
LPX 151 ± 2 0.2 5 ± 1  5% C16 Cer‐LPXs
Lipofectamine 
RNAiMAX® 
Liposomes  137 ± 12 0.6  26  ± 2 LF‐LP 
LPX 106  ± 3 0.6 22 ± 3 LF‐LPXs 
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Figure 1. Inhibition of luciferase in SKOV-3 cells by the lipoplexes in Opti-MEM® (dark 
grey bars) and following incubation of the lipoplexes for 1 h in ascites fluid (70 vol%) 
(white bars). The values in the graph represent the average from at least 3 experiments 
that were performed on different days.  
Figure 2 
 
 
 
 
 
Figure 2. Complexation efficiency of liposomes immediately following preparation in 
HEPES buffer (grey bars) and percentage of siRNA still complexed after incubation of 
the lipoplexes in 90 vol% of human ascites fluid during respectively 1 h (white bars) and 
24 h (dark grey bars).  
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Figure 3 
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Figure 3. fSPT size distributions of the different lipoplexes following incubation in 90 
vol% human ascites fluid at 37°C. (a) cationic LPXs, (b) 5% C16 Cer-LPXs and (c) LF-
LPXs. The dotted (pink) line corresponds to 5 µm in size aggregates. The Y-axis refers to 
the fraction (f) of nanoparticles that appear with the corresponding size on the X-axis.   
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Figure 4. Uptake of AF-488 siRNA labeled lipoplexes by SKOV-3 cells. Lipoplexes were 
prepared in HEPES buffer and added to the cells in Opti-MEM® following preparation 
as such (a) or after incubation of the lipoplexes for 1 h in human ascites fluid before adding 
them on the cells (b).  
 
 
 
 
 
 
 
Figure 5 
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Figure 5. Luciferase inhibition, following upside-down transfections, by LF-LPXs, 
respectively in Opti-MEM® and following incubation of the complexes for 1 h and 3 h in 
ascites fluid. The values in the graph represent the average from at least 3 experiments 
that were performed on different days.  
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